News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,586 Results
Type
Article (34660)
Company Profile (194)
Press Release (453732)
Section
Business (133047)
Career Advice (845)
Deals (23929)
Drug Delivery (78)
Drug Development (61759)
Employer Resources (87)
FDA (12381)
Job Trends (11644)
News (234296)
Policy (24199)
Tag
Academia (2405)
Africa (565)
Alliances (37302)
Alzheimer's disease (1070)
Antibody-drug conjugate (ADC) (54)
Approvals (12329)
Arizona (87)
Artificial intelligence (64)
Asia (27683)
Australia (4949)
Bankruptcy (184)
Best Places to Work (9957)
Biosimilars (53)
Biotechnology (135)
C2C Services and Suppliers (47284)
California (1339)
Canada (720)
Cancer (303)
Career advice (725)
Cell therapy (98)
China (103)
Clinical research (47488)
Collaboration (102)
Colorado (57)
Connecticut (57)
COVID-19 (2335)
Cystic fibrosis (69)
Data (153)
Diabetes (62)
Diagnostics (5162)
Drug pricing (68)
Earnings (45563)
Employer resources (76)
Europe (62973)
Events (86102)
Executive appointments (97)
FDA (12532)
Florida (193)
Funding (92)
Gene therapy (72)
Georgia (57)
GLP-1 (407)
Government (4333)
Healthcare (17290)
Hotbed/Location (331727)
Illinois (178)
Indiana (139)
Infectious disease (2357)
Inflammatory bowel disease (87)
Interviews (103)
IPO (11099)
Job creations (1800)
Job search strategy (638)
Kansas (74)
Layoffs (240)
Legal (4386)
Lung cancer (69)
Maine (56)
Manufacturing (58)
Maryland (306)
Massachusetts (1154)
Medical device (9944)
Medtech (9945)
Mergers & acquisitions (12773)
Metabolic disorders (202)
Michigan (84)
Minnesota (136)
Neuroscience (1179)
New Jersey (410)
New York (421)
NextGen Class of 2024 (5609)
Non-profit (4145)
North Carolina (475)
Northern California (619)
Obesity (129)
Ohio (81)
Opinion (144)
Patents (50)
Pennsylvania (459)
People (39251)
Phase I (16154)
Phase II (20433)
Phase III (15167)
Pipeline (94)
Postmarket research (1808)
Preclinical (6439)
Press Release (53)
Rare diseases (110)
Real estate (3304)
Regulatory (16248)
Research institute (2193)
Resumes & cover letters (145)
South America (738)
Southern California (554)
Startups (2726)
Texas (143)
United States (6320)
Vaccines (428)
Washington State (228)
Weight loss (108)
Date
Today (40)
Last 7 days (467)
Last 30 days (1853)
Last 365 days (31754)
2024 (21255)
2023 (33957)
2022 (44032)
2021 (47419)
2020 (46192)
2019 (39539)
2018 (29603)
2017 (23723)
2016 (23713)
2015 (27236)
2014 (20118)
2013 (16056)
2012 (16774)
2011 (17262)
2010 (15051)
488,586 Results for "target health".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
Guardant Health, Inc. (Nasdaq: GH) announced its research collaborators from Washington University’s Siteman Cancer Center will lead an oral presentation today at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting highlighting the potential role of liquid biopsy in addressing racial inequities in enrollment in clinical trials and in the use of targeted therapies for advanced breast cancer.
June 3, 2024
·
5 min read
Biotech Bay
Enspectra Health Receives FDA Breakthrough Device Designation for AI-powered Imaging Platform Targeting Skin Cancer
Enspectra Health, a health tech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its next generation AI-powered VIO™ Skin Platform (VIO) for the evaluation of lesions suspicious of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in select high risk populations.
June 5, 2024
·
2 min read
Press Releases
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
September 4, 2024
·
6 min read
Press Releases
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna’s COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
August 23, 2024
·
4 min read
Business
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders
Degron Therapeutics, the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, announced it has entered into a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.
May 23, 2024
·
3 min read
Genetown
Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge
Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED Challenge.
December 19, 2023
·
2 min read
Deals
Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions
Under a multi-year agreement announced Wednesday, Eli Lilly will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions.
September 4, 2024
·
2 min read
·
Kate Goodwin
Business
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Evotec SE announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.
May 30, 2024
·
11 min read
Drug Development
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Inc. announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
June 18, 2024
·
5 min read
Diabetes Researchers in China Demonstrate Early Insulin Therapy Significant Benefits Cardiovascular Health
Recently, Professor Jianping Weng of the University of Science and Technology of China and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their latest research on the effects of early insulin therapy on cardiovascular health in adults with Type 2 Diabetes Mellitus in the journal Signal Transduction and Targeted Therapy.
June 19, 2024
·
6 min read
1 of 48,859
Next